Maria Di Bartolomeo
Overview
Explore the profile of Maria Di Bartolomeo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
4222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al.
Nat Commun
. 2025 Jan;
16(1):704.
PMID: 39814812
No abstract available.
2.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, et al.
Nat Commun
. 2024 Nov;
15(1):10213.
PMID: 39587050
DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic...
3.
Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, et al.
Lancet Oncol
. 2024 Nov;
25(12):1539-1550.
PMID: 39557058
Background: Paclitaxel plus ramucirumab is recommended as a second-line treatment regimen in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer. We aimed to assess whether switch maintenance or early...
4.
Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al.
Gastric Cancer
. 2024 Jun;
27(4):672-674.
PMID: 38884884
No abstract available.
5.
Balzano G, Reni M, Di Bartolomeo M, Scorsetti M, Caraceni A, Rivizzigno P, et al.
Dig Liver Dis
. 2024 Jun;
57(2):370-377.
PMID: 38851973
Pancreatic and periampullary cancers pose significant challenges in oncological care due to their complexity and diagnostic difficulties. Global experiences underscore the crucial role of multidisciplinary collaboration and centralized care in...
6.
Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, et al.
Cancer Med
. 2024 May;
13(9):e7235.
PMID: 38716626
Background: First-line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in...
7.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, et al.
BMC Cancer
. 2024 May;
24(1):563.
PMID: 38711003
No abstract available.
8.
Morgagni P, Bencivenga M, Carneiro F, Cascinu S, Derks S, Di Bartolomeo M, et al.
Gastric Cancer
. 2024 Apr;
27(4):649-671.
PMID: 38634954
Background: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy...
9.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, et al.
BMC Cancer
. 2024 Apr;
24(1):436.
PMID: 38589856
Background: Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20%(1-3). The only potential curative treatment is surgical resection. However, despite complex surgical procedures...
10.
Kang Y, Ryu M, Di Bartolomeo M, Chau I, Yoon H, Kim J, et al.
Gastric Cancer
. 2024 Jan;
27(2):375-386.
PMID: 38281295
Background: Rivoceranib is an oral, selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. ANGEL (NCT03042611) was a global, randomized, double-blinded, placebo-controlled, phase 3 study evaluating rivoceranib as 3rd-line...